Aduro Biotech Inc. (NASDAQ:ADRO)‘s stock had its “buy” rating reissued by equities research analysts at FBR & Co in a research note issued to investors on Tuesday.

Other analysts have also recently issued research reports about the stock. Canaccord Genuity set a $30.00 target price on shares of Aduro Biotech and gave the company a “buy” rating in a research report on Monday, October 24th. Leerink Swann set a $14.00 target price on shares of Aduro Biotech and gave the company a “buy” rating in a research report on Monday, October 24th. Finally, Roth Capital reissued a “buy” rating and issued a $20.00 price target (down previously from $22.00) on shares of Aduro Biotech in a report on Thursday, October 27th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. Aduro Biotech has an average rating of “Hold” and an average target price of $21.33.

Analyst Recommendations for Aduro Biotech (NASDAQ:ADRO)

Shares of Aduro Biotech (NASDAQ:ADRO) opened at 13.80 on Tuesday. The stock’s market capitalization is $927.11 million. The company’s 50 day moving average price is $12.56 and its 200 day moving average price is $12.92. Aduro Biotech has a one year low of $7.26 and a one year high of $34.95.

Aduro Biotech (NASDAQ:ADRO) last issued its earnings results on Wednesday, November 2nd. The company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.45) by $0.09. The business had revenue of $3.79 million for the quarter, compared to the consensus estimate of $3.99 million. Aduro Biotech had a negative net margin of 72.04% and a negative return on equity of 23.45%. The business’s revenue was down 79.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.01 EPS. On average, analysts expect that Aduro Biotech will post ($1.34) earnings per share for the current fiscal year.

In related news, CEO Stephen T. Isaacs sold 27,273 shares of the company’s stock in a transaction on Monday, October 3rd. The shares were sold at an average price of $12.67, for a total value of $345,548.91. Following the completion of the transaction, the chief executive officer now directly owns 129,473 shares of the company’s stock, valued at approximately $1,640,422.91. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Jennifer Lew sold 6,360 shares of the company’s stock in a transaction on Monday, September 19th. The stock was sold at an average price of $14.95, for a total transaction of $95,082.00. Following the completion of the transaction, the insider now directly owns 48,955 shares of the company’s stock, valued at $731,877.25. The disclosure for this sale can be found here. 6.50% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently made changes to their positions in ADRO. BlackRock Fund Advisors raised its position in shares of Aduro Biotech by 62.0% in the second quarter. BlackRock Fund Advisors now owns 1,665,187 shares of the company’s stock worth $18,833,000 after buying an additional 637,486 shares during the last quarter. BVF Inc. IL bought a new position in shares of Aduro Biotech during the second quarter worth $5,809,000. State Street Corp raised its position in shares of Aduro Biotech by 237.9% in the second quarter. State Street Corp now owns 543,514 shares of the company’s stock worth $6,147,000 after buying an additional 382,654 shares during the last quarter. BlackRock Institutional Trust Company N.A. raised its position in shares of Aduro Biotech by 133.1% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 511,784 shares of the company’s stock worth $5,788,000 after buying an additional 292,264 shares during the last quarter. Finally, Oxford Asset Management bought a new position in shares of Aduro Biotech during the second quarter worth $3,245,000. 28.50% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This article was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another publication, it was copied illegally and republished in violation of US and international copyright & trademark legislation. The original version of this article can be read at https://www.thecerbatgem.com/2016/11/23/aduro-biotech-inc-adro-given-buy-rating-at-fbr-co.html.

Aduro Biotech Company Profile

Aduro Biotech, Inc is a clinical-stage immunotherapy company. The Company is focused on the discovery, development and commercialization of therapies that transform the treatment of various diseases. The Company has developed approximately three technology platforms, which include Live, Attenuated, Double-Deleted (LADD), Stimulator of Interferon Genes (STING) Pathway Activator and B-select monoclonal antibodies.

5 Day Chart for NASDAQ:ADRO

Receive News & Stock Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related stocks with our FREE daily email newsletter.